News & Analysis on Clinical Trial Services & Contract Research And Development
Since they were first described in 1998, the existence of so-called nanobacteria - tiny RNA-based organisms that form microscopic mineral structures that have been blamed for causing calcified deposits in diseases such as atherosclerosis and kidney...
After acquiring local firm Erre Emme Reference Mterials, LGC Promochem has opened a new sales office in Italy as part of its strategy to expand its network of operations across Europe.
Pierre Fabre shuts down a facility manufacturing over-the-counter pharmaceutical products at its Veyron & Froment subsidiary in Marseille, blaming the move on France's de-reimbursement strategy.
Micap, which specialises in using yeast and other organisms as microcapsules for protecting active compounds, is set to expand its business after extricating itself from an 'onerous' license with Unilever Bestfoods.
Like many life sciences companies before it, Crucell of the Netherlands has started a major shift in strategy from a technology platform company to one involved in in-house product development. Could this put pressure on its well-established and...
Applied Biosystems has introduced a system for rapidly identifying and characterising potential antibody, diagnostic and therapeutic candidates. The 8500 Affinity Chip Analyser can detect and measure up to 400 antibody binding interactions...
Just ahead of the Lab Automation Europe and International Biotech conferences in London this week, DrugResearcher.com spoke with Kevin Hrusovsky, the chief executive of Caliper Technologies, to get his take on the current state of play in how...
German drug major Bayer has entered into a collaboration with Artemis Pharmaceuticals focusing on the development of genetically-engineered mice that are designed to have human-like biology. The ArteMice will be used in Bayer's drug discovery...